Can Enclomiphene Get Testosterone Over 1,000? What the Clinical Trials Actually Show

Key claims & what the clinical trials actually show (enclomiphene vs “1,000 ng/dL”)

Why “1,000 ng/dL” matters

• The number is treated as a Google/benchmark “round number” and near the upper end of what natural production might reach.
• It’s important to remember this is a blood level at a specific time, not a dosing target.

Who was studied

• Trial participants were not healthy with normal testosterone.
• They had low baseline testosterone, commonly ≤ ~300 ng/dL on two early-morning draws.

Starting points matter

• Even if enclomiphene increases testosterone substantially, starting from ~200–295 may still leave a large gap to reach 1,000 ng/dL.

The “wheel study” (2013): the only one with enough sampling detail

• Highest enclomiphene dose: 2 out of 272 samples crossed >1,000
• Lower enclomiphene doses: 0 crossed >1,000
• Testosterone gel comparator: the speaker argues the way figures are presented hides context, citing 305-level and >1,000 related counts and claiming per-person/per-sample details are obscured.

Interpretation warning: “Crossing 1,000” may refer to samples, not necessarily people consistently achieving >1,000. A single subject could account for a “crossing” at one timepoint. The video also emphasizes the literature may be silent or non-publishing around threshold handling (e.g., stopping counting at 500 in some contexts).

---

What top-line numbers look like on averages

• Published average outcomes cluster well below 1,000, roughly around 404–604 ng/dL (as described by the speaker).
• Even when studies disagree, the ceiling on averages doesn’t approach 1,000.
• The speaker claims the highest reported enclomiphene figure in the broader literature is ~805, from a weak/limited retrospective study that may not isolate enclomiphene cleanly and starts from a different baseline.

---

Mechanism: why enclomiphene likely can’t “scale up” to 1,000 the same way TRT does

Enclomiphene’s action

• Enclomiphene blocks estrogen signaling in the brain, increasing LH.
• Higher LH stimulates the testicles to make more testosterone.

Therefore the ceiling is biological

• The increase is limited by your testes’ capacity—more dose doesn’t necessarily produce proportional increases.

Dose response doesn’t equal proportional results

• In a 14-day dose-ranging experiment, testosterone rose with dose (dose-responsive),
• but levels plateaued in a band of roughly ~400–700 ng/dL, even at higher enclomiphene doses.

Comparators (gel/injected testosterone)

• Exogenous testosterone (gel/injection) can push levels past normal natural limits more easily because you’re adding hormone directly.
• Feedback mechanisms then suppress endogenous production, but exogenous dosing can still drive higher blood levels.

---

Key wellness strategies / self-care / productivity tips (what’s emphasized)

This section is more “strategy” framing than medical protocol. The transcript does not provide a concrete, step-by-step medical plan.

Use a “multi-pathway” approach

• The speaker argues that focusing on one mechanism can create other limiting factors.
• They claim better real-world outcomes come from synergy (enclomiphene plus other supporting agents), rather than enclomiphene alone.

Don’t waste time (behavioral/productivity framing)

• “A day natural is a day wasted” (speaker’s urgency/motivation message).

“Read between the lines” (critical thinking habit)

• Treat published trials as potentially shaped by:
  • what outcomes they choose to report
  • threshold choices
  • counting rules
  • incomplete reporting
• Consider anecdotal/community data as hypothesis-generating signals for where to look—while acknowledging it’s not the same as evidence.

Note: The transcript does not provide a concrete, step-by-step protocol; the speaker says detailed protocols are shared elsewhere and may be censored if fully spelled out.

---

Sources / presenters mentioned

• “Wheel study” (2013): randomized, single-blind study discussed in detail (enclomiphene doses vs testosterone gel)
• Bazin study (2001), NIH-funded: laboratory-controlled study using GnRH agonist + injected testosterone; used to illustrate that injected testosterone can pass higher thresholds
• Repros Therapeutics: sponsor/employer of authors; alleged involvement in trial design/reporting incentives
• Government/regulatory trial registries: referenced as places where results are posted (no specific registry IDs named)
• Video speaker / presenter: Not named in the provided subtitles